Synthetic Biologics(TOVX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2024 Operational Highlights and Financial Results - VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for metastatic Pancreatic Ductal Adenocarcinoma (PDAC), is expected to complete enrollment in the third quarter of 2024- - Received Fast Track Designation (FTD) Granted by the U.S. Food and Drug Administration (FDA) for VCN-01 for the treatment of metastatic pancreatic adenocarcinoma- - Received Rare Pediatric Disease Design ...